Pancreatic Neoplasms

The supplied grounding supports hereditary predisposition in some cases, including pathogenic variants associated with increased pancreatic cancer risk. BRCA1/2-related cancer syndromes and Li-Fraumeni syndrome are specifically mentioned as inherited contexts in which pancreatic cancer risk is elevated.

The literature grounding emphasizes pancreatic ductal adenocarcinoma biology, including late diagnosis, early metastasis, and limited response to chemotherapy or radiotherapy. Chemoresistance is described as multifactorial and involving interactions among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment, with co-studied mechanisms including gene expression regulation, signal transduction, lymphocyte activation, microbiota, and BRCA2 germ-line mutation.

Inherited pathogenic variants associated with hereditary cancer syndromes increase risk, including BRCA1/2-related syndromes and Li-Fraumeni syndrome. The grounding also notes that pancreatic cancer is often diagnosed at an advanced stage and that high-risk individuals are a focus of screening and genetic assessment, but it does not support additional specific risk factors.

Treatment is described at the modality level as surgery for resectable disease, with prolonged survival achieved only by resection with macroscopic tumor clearance. Systemic therapy for locally advanced and metastatic disease includes chemotherapy combinations such as gemcitabine-based therapy and fluorouracil/leucovorin with irinotecan and oxaliplatin, and newer targeted therapies are also noted; neoadjuvant radiochemotherapy is discussed for selected patients.